HyperBranch Medical Technology
HyperBranch Medical Technology is a Durham, NC-based medical device company that develops hydrogel-based dural sealants (Adherus AutoSpray line) for watertight closure in cranial procedures, commercialized through Stryker's distribution network to neurosurgical and craniomaxillofacial hospital departments.
- Company typePrivate
- Founded2003
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HyperBranch Medical Technology does
HyperBranch Medical Technology is a privately held medical device company founded in 2003 and headquartered in Durham, North Carolina, that develops and commercializes products for the traumatic or surgically-induced wound market. The company's core offering centers on its Adherus line of hydrogel-based dural sealants — specifically the Adherus AutoSpray Dural Sealant and the Adherus AutoSpray ET Dural Sealant (an extended-tip applicator variant) — which are indicated for patients aged 13 and older as adjuncts to standard dural repair methods (such as sutures) to provide watertight closure during cranial procedures. The hydrogel technology is engineered to maintain burst pressure strength above physiological intracranial pressure and to absorb over approximately 90 days, with clinical evidence from a prospective, randomized, controlled, multicenter pivotal trial demonstrating 99.1% effectiveness in preventing cerebrospinal fluid (CSF) leaks at 14-day follow-up and 91.2% overall success rate (non-inferiority p=0.005) versus active control.
The company's go-to-market is built on an enterprise field sales model executed through Stryker's established medical device distribution network, targeting neurosurgical and craniomaxillofacial departments at hospitals and surgical centers globally. HyperBranch operates with 11-50 employees under the leadership of John Conn, President & CEO and member of the Board of Directors. The company has raised approximately $18.6 million across multiple funding rounds between 2005 and 2013, with investors including The Aurora Funds (lead investor in the 2005 Series 2) and H.I.G. Capital. Pricing is not publicly disclosed; healthcare facilities request product information through Stryker's sales channel, and products are sold as one-time-purchase medical device units consumed during cranial surgical procedures.
HyperBranch Medical Technology firmographics
Firmographics- Name
- HyperBranch Medical Technology
- Website
- https://hyperbranch.com
- Company type
- Private
- Founded year
- 2003
- Headcount range
- 11–50 employees
- Short description
- HyperBranch Medical Technology is a Durham, NC-based medical device company that develops hydrogel-based dural sealants (Adherus AutoSpray line) for watertight closure in cranial procedures, commercialized through Stryker's distribution network to neurosurgical and craniomaxillofacial hospital departments.
- Ownership category
- akta.pro rank
HyperBranch Medical Technology industry classification
Industry- Product category
- Neurosurgical Medical Devices
- NAICS
- Adhesive Manufacturing (32552)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)
- akta.pro secondary industry
- Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)
Keywords
Where HyperBranch Medical Technology is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
HyperBranch Medical Technology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Sale of medical device products (dural sealants) to healthcare facilities through Stryker's distribution network. Products are sold as adjuncts to surgical procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
HyperBranch Medical Technology product offering
Product offeringCore offering
HyperBranch Medical Technology develops and commercializes hydrogel-based dural sealants—Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant—used as an adjunct to sutures to achieve watertight closure of the dura mater during cranial neurosurgical and craniomaxillofacial procedures, addressing the traumatic or surgically-induced wound market. The sealants are distributed through Stryker's sales channel and are targeted at neurosurgery and skull-base surgical departments in hospitals and surgical centers.
Product overview
HyperBranch Medical Technology's product portfolio, as represented in the available source data, consists of medical device products for cranial and neurosurgical procedures. The core offering includes the Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant product lines — hydrogel-based sealants designed as adjuncts to standard dural repair methods to provide watertight closure during cranial procedures. These products are positioned within the craniomaxillofacial and cranial closure product categories. Note: The source data shows these products as part of Stryker's craniomaxillofacial portfolio; the relationship between HyperBranch Medical Technology and Stryker is not specified in the source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Adherus AutoSpray Dural Sealant
Quantifiable outcome
- 99.1% effectiveness in preventing CSF leaks through 14 days post-operative follow-up
- +3 more outcomes
Companies that use HyperBranch Medical Technology
Customer profileSegments1 record
Ideal customer profiles1 record
HyperBranch Medical Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
HyperBranch Medical Technology partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights3 records
HyperBranch Medical Technology competitors and assessment
Company assessmentDirect peers
- Integra LifeSciences: Integra markets DuraSeal, the leading competing hydrogel/polymer dural sealant used for watertight closure in cranial and spinal procedures. Most directly comparable competitor to Adherus, serving the same neurosurgical customer base with the same adjunct-to-sutures value proposition.
Broad incumbents
- Baxter International: Baxter owns Tisseel and Floseal, two widely used surgical sealants and hemostats used across multiple surgical specialties. Comparable as a broader surgical sealant incumbent with overlapping operating-room customers, though its portfolio spans far beyond cranial procedures.
- Ethicon (Johnson & Johnson): Ethicon markets Evicel and other surgical sealants/hemostats and is the dominant surgical sutures supplier globally. Comparable as an incumbent with deep surgeon relationships and competing sealant chemistries in the same cranial and broader neurosurgical workflows.
- Medtronic: Medtronic has a large neurosurgical and cranial portfolio and historically has competed in the dural repair space through legacy products and partnerships. Comparable as a broad neurosurgical incumbent with overlapping surgical-suite customers and resources to consolidate the sealant category.
- B. Braun (Aesculap): B. Braun's Aesculap division supplies surgical instruments, dural substitutes, and sealants used in neurosurgical procedures. Comparable as a broad neurosurgical device incumbent with overlapping surgical-suite customers and an interest in the dural closure category.
Emerging players
- Tissuemed: Tissuemed develops tissue adhesives and sealants, including products positioned for dural and surgical sealing applications. Comparable as a smaller specialist player in surgical sealants with overlapping chemistry-driven value proposition but narrower geographic/commercial reach than Adherus via Stryker.
- Polyganics: Polyganics develops bioresorbable polymer-based sealants and devices for neurosurgical and peripheral nerve repair applications. Comparable as an emerging polymer-chemistry specialist with overlapping bioresorbable sealant technology relevant to the same cranial and nerve-repair use cases.
Others
- Stryker: Stryker is HyperBranch's exclusive distribution partner for the Adherus line and also operates a broad neurosurgical and craniomaxillofacial portfolio. Relevant as the commercial channel that defines Adherus's reach and as a potential strategic acquirer of HyperBranch.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
HyperBranch Medical Technology social profiles
Digital presenceHyperBranch Medical Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
HyperBranch Medical Technology leadership team
Management profileNumber of profiles
Profiles1 record
HyperBranch Medical Technology funding detail
Funding detailFunding overview
Funding rounds9 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HyperBranch Medical Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HyperBranch Medical Technology
What does HyperBranch Medical Technology do?
HyperBranch Medical Technology develops and commercializes hydrogel-based dural sealants—Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant—used as an adjunct to sutures to achieve watertight closure of the dura mater during cranial neurosurgical and craniomaxillofacial procedures, addressing the traumatic or surgically-induced wound market. The sealants are distributed through Stryker's sales channel and are targeted at neurosurgery and skull-base surgical departments in hospitals and surgical centers.
Is HyperBranch Medical Technology a public or private company?
HyperBranch Medical Technology is a private company. It is classified as venture growth investor backed.
When was HyperBranch Medical Technology founded?
HyperBranch Medical Technology was founded in 2003. It employs 11 to 50 people.
Where is HyperBranch Medical Technology based?
HyperBranch Medical Technology is headquartered in Durham, United States, in the North America region.
How does HyperBranch Medical Technology make money?
One revenue line is on record: medical Device Sales.
Who are HyperBranch Medical Technology's main competitors?
Integra LifeSciences is listed as a direct peer. Broad incumbents are Baxter International, Ethicon (Johnson & Johnson), Medtronic and B. Braun (Aesculap). Emerging players are Tissuemed and Polyganics. Stryker is listed as an others.
Does HyperBranch Medical Technology have an API?
No public API is recorded for HyperBranch Medical Technology.
What industry is HyperBranch Medical Technology in?
HyperBranch Medical Technology's product category is Neurosurgical Medical Devices. Its primary akta.pro industry code is HLAHALAD, Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips), with a secondary code of HLAHADAL, Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets). Its NAICS code is 32552 and its SIC code is 3841.